2 ISC NEWS DAY 2 | THURSDAY, FEBRUARY 6, 2025 StrokeConference.org #ISC25 THURSDAY, FEB. 6 11 a.m.-12:30 p.m. Main Event Hall LB16 | TRANScranial Direct Current Stimulation for Post-Stroke Motor Recovery: A Phase 2 Study (TRANSPORT2) Main Results Wayne Feng, Duke University School of Medicine, Chapel Hill, North Carolina LB17 | Intensive Blood Pressure Lowering After Thrombectomy in Ischemic Stroke Patients: A Randomized Clinical Trial Xuening Zhang, West China Hospital, Chendu, China LB18 | Coordinated, Collaborative, Comprehensive, Family-Based, Integrated, Technology-Enabled Post-Stroke Care George Howard, University of Alabama-Birmingham, Birmingham, Alabama LB19 | The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial 2 Final Results Ken Butcher, University of New South Wales, Randwick, NSW, Australia LB20 | Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, DoubleBlinded Clinical Trial Issam A. Awad, University of Chicago Medical Center, Chicago, Illinois CLOSING MAIN EVENT FRIDAY, FEB. 7 11 a.m.-1:05 p.m. Main Event Hall LB37 | Effects of Direct Oral Anticoagulants Versus No Anticoagulation in the Prevention of Stroke in Intracerebral Haemorrhage Survivors With Atrial Fibrillation (PRESTIGE-AF) Trial Roland Veltkamp, Imperial College London, London, United Kingdom LB38 | Intra-Arterial Tenecteplase Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization (ANGEL-TNK) — A Multicenter, Prospective, Randomized, OpenLabel, Blinded Endpoint Trial Miao Zhongrong, Beijing Tiantan Hospital, Beijing, China LB39 | The Optimal Dosage of Adjunctive Intra-Arterial Tenecteplase Following Successful Endovascular Thrombectomy in Patients With Large Vessel Occlusion Acute Ischemic Stroke (DATE) Trail Xianhua Hou, The First Affiliated Hospital, Army Medical University, Chongqing, China LB40 | Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral Tissue in Patients With Large Vessel Occlusion (ETERNALLVO): A Multicenter, Prospective, Open-Label, Blinded Endpoint, Controlled, Phase 3, Superiority Trial Vignan Yogendrakumar, The Ottawa Hospital, Ottawa, ON, Canada LB41 | Treatment With Intravenous Alteplase in Ischemic Stroke Patients With Onset Time Between 4.5 And 24 Hours Min Lou, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China LB42 | Intra-Arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter Randomized Trial Yamei Tang, Sun Yat-sen Memorial Hospital, Guangzhou, China LB43 | A Randomized Controlled Trial of Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherosclerosis: The ATISNVAF Trial Shuhei Okazaki, NHO Osaka National Hospital, Osaka, Japan LB44 | Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus (LAMP): A Randomized Clinical Trial Huili Zhu, The First Affiliated Hospital of Jinan University, Guangzhou, China LB45 | BXOS110 for Acute Ischemic Stroke Treatment (BEST): A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial Yarong Ding, Beijing Tiantan Hospital, Beijing, China See Online Program Planner for more information. Learning Studios and symposia scheduling 6:30-8 a.m. Innovations and Expert Guidance in Antiplatelet Reversal and Bleeding Management Supporter: Clinical Care Options, LLC JW Marriott Los Angeles, Platinum Ballroom E 5:30-7:30 p.m. Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF Total CME supported by an educational grant from Bristol Myers Squibb and Johnson & Johnson Innovative Medicine Alliance JW Marriott Los Angeles, Room: Gold 3-4 (Ground Floor) 6-7:30 p.m. Staying Ahead in Stroke Prevention: The Rise of New Anticoagulation Approaches Medscape Education on behalf of Bayer JW Marriott, Ballroom Platinum A-D Satellite Symposia Learning Studios THURSDAY, FEB. 6 Late-Breaking Science 9:15-9:45 a.m. Advancing Stroke Care: Deepening the Collaboration Between Neurology and Cardiology Medtronic Learning Studio I 10-10:30 a.m. Evolution of Stroke Treatment and Building a CSC With New 088 Technology Terumo Neuro Learning Studio I 10-10:30 a.m. Scaling Stroke Triage With AI: Virtual Innovation for Neuroscience Excellence (VINE) Sevaro Learning Studio II in Meeting Room 306AB 12:45-1:15 p.m. Considerations and Learnings With Newer Generation Flow Diverters Medtronic Learning Studio I 12:45-1:15 p.m. Disrupting the Status Quo: Aldosterone in the Pathogensis of Hypertension AstraZeneca Learning Studio II in Meeting Room 306AB 1:30-2 p.m. Build a Thriving Telestroke Program: Best Practices and Common Pitfalls TeleSpecialists Learning Studio I 2:15-2:45 p.m. Optimizing Blood Pressure Variability (BPV): Management Strategies for Stroke Care Chiesi Learning Studio I 3:30-4 p.m. Cracking the Code of Cryptogenic Stroke: Robotic TCD for PFO Detection NeuraSignal Learning Studio I 3:30-5 p.m. Fourth Annual Company Showcase NHLBI and NINDS Showcase Learning Studio II in Meeting Room 306AB These events are not part of the official International Stroke Conference 2025 as planned by the International Stroke Conference Program Committee.
RkJQdWJsaXNoZXIy MjI2NjI=